Stable iron oligosaccharide compound

    公开(公告)号:US10414831B2

    公开(公告)日:2019-09-17

    申请号:US16178943

    申请日:2018-11-02

    发明人: Hans Andreasen

    摘要: The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, the content of dimes saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia.

    Therapy for treatment or prevention of conditions associated with bleeding or hypocoagulation

    公开(公告)号:US10407488B2

    公开(公告)日:2019-09-10

    申请号:US15034385

    申请日:2014-11-04

    摘要: The present application generally relates to methods to prevent or treat bleeding and/or hypocoagulation in an individual in need thereof, and compositions for use in such methods. The methods comprise administration of FVa, preferably an APC resistant FVa (such as superFVa), alone or in combination with FVIIa, preferably rhFVIIa (such as NovoSeven® or another FVIIa having enhanced activity or half-life). When administered in combination, FVa and FVIIa elicit a synergistic benefit when used to treat or prevent bleeding or hypocoagulation in subjects in need thereof, e.g., subjects with a genetic disorder such as hemophilia or an acquired bleeding disorder or other condition associated with bleeding or hypocoagulation such as hemorrhagic stroke or shock, trauma, surgery or dysmenorrhea or individuals who produce inhibitory antibodies against procoagulants such as FVIII or FIX or who have been administered an overdose of an anticoagulant drug such as a direct Xa or direct thrombin inhibitor or a Novel Oral Anti-Coagulant (NOAC) or demonstrate unexplained bleeding. Also, the invention relates to the use of a superFVa alone or in combination with FVIIa or other procoagulant or prohemostatic agent to prevent, treat or reverse APC-associated bleeding, e.g., as the result of APC overproduction (such as through serious injury and/or hemorrhagic shock) or APC or other anticoagulant therapy, e.g., in the treatment of inflammatory disorders or sepsis disease.

    Mat
    6.
    外观设计
    Mat 有权

    公开(公告)号:USD856027S1

    公开(公告)日:2019-08-13

    申请号:US29648838

    申请日:2018-05-24

    申请人: Chih-Yin Chang

    设计人: Chih-Yin Chang

    Elastomeric bushing having embedded structures for improved thermal conductivity and damping capacity

    公开(公告)号:US10352394B2

    公开(公告)日:2019-07-16

    申请号:US15468996

    申请日:2017-03-24

    摘要: An elastomeric bushing for vehicle suspension includes inner and outer metal tubes, an elastomeric material between the tubes, and one or more bundles of woven wires (ropes or cables) in entangled or mesh form wherein at least a portion of the wires contact at least one of the tubes. The bushing has enhanced thermal conductivity via metal-to-metal contact and improved damping capacity to reduce heat buildup inside the material upon cyclic loading and unloading. The metallic wire rope, metallic wire ropes or wire mesh are embedded in the elastomeric material during injection molding where the ends of the wire ropes are attached to the opposing side walls of the inner and outer metal tubes or are spaced apart from the opposing side walls for tunability and to thereby enable a more effective dissipation of the heat generated inside the elastomeric bushing during its usage into the kinematically connected suspension members.